- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.10. | Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline | ||
| 14.10. | Agilent spends $240M upfront to buy digital pathology specialist Proscia | ||
| 13.10. | Insulet's Omnipod Discover platform sees full market release in US | ||
| 13.10. | BioNTech's mRNA cancer vaccine fails phase 3 test, significantly denting analysts' confidence | ||
| 13.10. | Biotech builder Paragon imports Apogee's top brass after AbbVie buyout | ||
| 13.10. | Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race | ||
| 13.10. | Pfizer inks $500M Enodia pact to join Lilly in emerging protein degrader field | ||
| 13.10. | Nurix drops one BTK degrader as momentum builds behind Roche-partnered option | ||
| 12.10. | Roche sets sights on FDA approval decision of July 2027 with updated eye drug data | ||
| 12.10. | Tortugas' schizophrenia drug proves worth in phase 2 Hansoh trial in China | ||
| 12.10. | BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth | ||
| 12.10. | Merck's deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of 'limited' potential | ||
| 10.10. | Parkinson's-focused Aspen and bispecific biotech Bambusa plan IPOs | ||
| 09.10. | Ferass Abuzaina named Worldwide President of Surgery at BD | ||
| 09.10. | GSK drinks in Chai Discovery's AI models after wet-lab validation | ||
| 09.10. | 'We're making a lot of progress': How Nobel-winning optogenetics is being harnessed by biotechs | ||
| 09.10. | Chutes & Ladders-Vir looks to Liu to lead late-stage push | ||
| 09.10. | Lilly-backed TRex Bio rakes in $117M IPO, while hypertension biotech Retension Pharma reveals $45M listing | ||
| 08.10. | iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa | ||
| 08.10. | AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic | ||
| 08.10. | Endeavor's threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor | ||
| 08.10. | 'It's just survival now': Why is almost a third of Boston's life sciences lab space sitting vacant? | ||
| 08.10. | Zealand Pharma, Roche's 'intriguing' weight loss for amylin drug soured by blood sugar data | ||
| 08.10. | Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave's asset | ||
| 08.10. | Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.